MiR-378a-3p Acts as a Tumor Suppressor in Colorectal Cancer Stem-Like Cells and Affects the Expression of MALAT1 and NEAT1 lncRNAs.
MALAT1
MiR-378a-3p
NEAT1
colorectal cancer
colorectal cancer stem-like cells
lncRNAs
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
02
2022
accepted:
30
05
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
MiR-378a-3p plays a critical role in carcinogenesis acting as a tumor suppressor, promoting apoptosis and cell cycle arrest and reducing invasion and drug resistance in several human cancers, including colorectal cancer (CRC), where its expression is significantly associated with histological classification and prognosis. In this study, we investigated the biological and cellular processes affected by miR-378a-3p in the context of CRC carcinogenesis. In agreement with the literature, miR-378a-3p is downregulated in our cohort of CRC patients as well as, in 15 patient-derived colorectal cancer stem-like cell (CRC-SC) lines and 8 CRC cell lines, compared to normal mucosae. Restoration of miR-378a-3p restrains tumorigenic properties of CRC and CRC-SC lines, as well as, significantly reduces tumor growth in two CRC-SC xenograft mouse models. We reported that miR-378a-3p modulates the expression of the lncRNAs MALAT1 and NEAT1. Their expression is inversely correlated with that of miR-378a-3p in patient-derived CRC-SC lines. Silencing of miR-378a-3p targets, MALAT1 and NEAT1, significantly impairs tumorigenic properties of CRC-SCs, supporting the critical role of miR-378a-3p in CRC carcinogenesis as a tumor-suppressor factor by establishing a finely tuned crosstalk with lncRNAs MALAT1 and NEAT1.
Identifiants
pubmed: 35814429
doi: 10.3389/fonc.2022.867886
pmc: PMC9263271
doi:
Types de publication
Journal Article
Langues
eng
Pagination
867886Informations de copyright
Copyright © 2022 Castellani, Buccarelli, Lulli, Ilari, De Luca, Pedini, Boe, Felli, Biffoni, Pilozzi, Marziali and Ricci-Vitiani.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Cancer. 2020 May;122(11):1630-1637
pubmed: 32238921
Lancet. 2000 Mar 25;355(9209):1041-7
pubmed: 10744089
Cancer Cell Int. 2015 Apr 15;15:40
pubmed: 25977643
Int J Cancer. 2021 Mar 15;148(6):1489-1498
pubmed: 33128777
Tumour Biol. 2016 Feb;37(2):2095-103
pubmed: 26346167
Physiol Rev. 2016 Oct;96(4):1297-325
pubmed: 27535639
J Exp Clin Cancer Res. 2020 Mar 24;39(1):54
pubmed: 32209115
Biochim Biophys Acta. 2016 Jan;1859(1):192-9
pubmed: 26434412
Mol Biol Rep. 2019 Aug;46(4):4175-4183
pubmed: 31123908
Nat Rev Cancer. 2011 Jan;11(1):59-67
pubmed: 21160526
Pathol Oncol Res. 2017 Jul;23(3):651-656
pubmed: 28013491
Int J Mol Sci. 2018 Dec 27;20(1):
pubmed: 30591689
Cell Prolif. 2019 Jan;52(1):e12526
pubmed: 30407674
Sci Rep. 2015 Aug 10;5:13170
pubmed: 26255816
Noncoding RNA Res. 2020 Aug 23;5(3):125-134
pubmed: 32954092
Oncogenesis. 2013 Sep 16;2:e71
pubmed: 24042735
Mol Cell. 2014 Sep 4;55(5):791-802
pubmed: 25155612
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Oncotarget. 2016 Jul 12;7(28):44113-44128
pubmed: 27286453
Genes Dev. 2016 Jan 1;30(1):34-51
pubmed: 26701265
Nature. 2007 Jan 4;445(7123):111-5
pubmed: 17122771
Br J Cancer. 2014 Feb 18;110(4):1001-7
pubmed: 24423916
World J Surg Oncol. 2020 Oct 6;18(1):261
pubmed: 33023572
Cancer Res. 2013 Feb 1;73(3):1180-9
pubmed: 23243023
Int J Mol Med. 2018 Jul;42(1):381-391
pubmed: 29693138
Prz Gastroenterol. 2019;14(2):89-103
pubmed: 31616522
Onco Targets Ther. 2018 May 14;11:2797-2804
pubmed: 29785127
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Biomed Pharmacother. 2018 Nov;107:1410-1417
pubmed: 30257357
BMC Genomics. 2007 Feb 01;8:39
pubmed: 17270048
Neoplasma. 2021 Mar;68(2):240-252
pubmed: 33440992
Oncol Rep. 2019 Nov;42(5):1957-1971
pubmed: 31432186
Gene. 2020 Mar 20;731:144324
pubmed: 31904498
Mol Genet Genomic Med. 2020 Apr;8(4):e1125
pubmed: 32077635
Cell Rep. 2012 Jul 26;2(1):111-23
pubmed: 22840402
Eur J Cancer. 2014 Apr;50(6):1207-21
pubmed: 24412052
Biomed Pharmacother. 2014 Oct;68(8):911-6
pubmed: 25458789
Mol Cancer. 2017 Jun 14;16(1):104
pubmed: 28615056
J Exp Med. 2004 Nov 15;200(10):1257-66
pubmed: 15545353
Pathol Res Pract. 2015 Aug;211(8):557-69
pubmed: 26092594
Carcinogenesis. 2021 Nov 12;42(11):1370-1379
pubmed: 34313719
J Clin Oncol. 2000 Jan;18(1):136-47
pubmed: 10623704
World J Gastroenterol. 2010 Aug 21;16(31):3871-7
pubmed: 20712047
Cancer Cell Int. 2022 Mar 19;22(1):126
pubmed: 35305641
Onco Targets Ther. 2016 Apr 13;9:2143-51
pubmed: 27110130
Int J Mol Sci. 2020 May 20;21(10):
pubmed: 32443824
Biochem Pharmacol. 2021 Aug;190:114657
pubmed: 34144008
N Engl J Med. 2019 Jan 3;380(1):57-70
pubmed: 30601736
Mol Oncol. 2019 Jan;13(1):46-60
pubmed: 30430751
J Cell Biochem. 2020 Mar;121(3):2225-2235
pubmed: 31692053
Mol Med Rep. 2018 Mar;17(3):4581-4588
pubmed: 29328399